The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer.
 
Akash Patnaik
Honoraria - Clovis Oncology; Janssen Oncology; Merck; Prime Oncology
Consulting or Advisory Role - Janssen Oncology; Jounce Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Progenics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; Merck; Prime Oncology
 
Priyanka Duttagupta
No Relationships to Disclose
 
Kiranj Chaudagar
No Relationships to Disclose
 
Raanan Alter
No Relationships to Disclose
 
Hanna Hieromnimon
No Relationships to Disclose
 
Russell Zelig Szmulewitz
Honoraria - Astellas Pharma
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
Research Funding - Abbvie; Astellas Pharma; Incyte; Janssen Oncology; Macrogenics
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Gini F. Fleming
Honoraria - Curio Science
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); Compugen (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Forty Seven (Inst); Genentech (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Leap Therapeutics (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
(OPTIONAL) Uncompensated Relationships - TTC Oncology
 
Walter Michael Stadler
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; CVS Caremark; Eisai; Merck; Pfizer; Roche/Genentech; Sotio
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Seagen (I); Tesaro (Inst); X4 Pharma (Inst)
Other Relationship - American Cancer Society; UpToDate